Acuity reports $1.2 billion quarterly sales
Acuity (NYSE:AYI) reported fiscal fourth-quarter net sales of $1.2 billion for the quarter ended August 31, 2026, with diluted earnings per share rising 56% to $5.63.
Acuity (NYSE:AYI) reported fiscal fourth-quarter net sales of $1.2 billion for the quarter ended August 31, 2026, with diluted earnings per share rising 56% to $5.63.
Oil prices rose around 2% on Thursday after China suspended oil product exports to regions outside Hong Kong and Macau, adding pressure to global fuel markets affected by supply disruptions.
United Therapeutics (NASDAQ:UTHR) announced that a Delaware federal court found Liquidia’s Yutrepia infringes two claims of a patent covering inhaled treprostinil treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
STARZ (NASDAQ:STRZ) warned that Verizon Fios customers may lose access to its services unless the companies reach a new distribution agreement, affecting STARZ channels, On Demand content and the STARZ app through Fios.
Li Auto (NASDAQ:LI) delivered 31,817 vehicles in September 2026, with cumulative deliveries reaching 1,833,651 vehicles as the company expanded its battery-electric vehicle lineup.
Tigo Energy (NASDAQ:TYGO) announced it will showcase its GO Optimized Energy Storage Solution at Smart Energy Forum 2026 in Prague, following increased deployment of its solar technology across the Czech market.
NIO (NYSE:NIO) delivered 37,408 vehicles in September 2026, representing a 7.7% year-over-year increase across its NIO, ONVO and FIREFLY vehicle brands.
Regeneron (NASDAQ:REGN) expanded its antibody alliance with Sanofi through an agreement covering four long-acting antibody candidates and a $1 billion upfront payment to Regeneron.
XPENG (NYSE:XPEV) delivered 41,256 vehicles in September 2026, with monthly deliveries increasing 5% compared with the previous month and third-quarter deliveries reaching 118,390 vehicles.
Oculis (NASDAQ:OCS) joined the National Multiple Sclerosis Society’s Campaign to End MS as an industry partner focused on advancing research and care related to vision problems in multiple sclerosis.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy